Loading clinical trials...

The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation | Clinical Trials | Clareo Health

COMPLETEDNA

The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation

Open-label, Prospective Study on the Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation

NCT06080035•Integrative Skin Science and Research

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the effects of Cetyl Tranexamate Mesylate on acne-related hyperpigmentation through a specific delivery form known as TeraCeutic TXVector.

Detailed Description

Hyperpigmentation is characterized as an increase in pigment on the skin and is a common skin condition in individuals with skin types III to VI on the Fitzpatrick skin classification scale. Hyperpigmentation can be localized to an area in the form of post-inflammatory hyperpigmentation or diffused in the form of melasma. One of the treatments that are used to treat hyperpigmentation is tranexamic acid (TXA) which is a third-generation bioactive and is formally known to work as a plasmin inhibitor. Since TXA is hydrophilic in nature and has a strong hydrogen-bonding capacity, it has an insufficient skin permeability. Similar to TXA esters, Cetyl Tranexamate Mesylate (CTM) is hypothesized to have greater permeability and this study will evaluate the effects of CTM on the appearance of post-inflammatory hyperpigmentation.

Eligibility

Age

14 - 45 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Males and females between the ages of 14 years of age until 55 years of age
•Individuals experiencing 3 different areas minimum of facial post-inflammatory hyperpigmentation in those with acne

Exclusion Criteria

•Individuals who are pregnant or breastfeeding.
•Prisoners.
•Adults unable to consent.
•Those who are unwilling to discontinue hydroquinone, vitamin A/C/E, azelaic acid, kojic acid, bakuchiol, licorice root, retinol, niacinamide, alpha arbutin, and oral or topical tranexamic acid for two weeks to meet the washout criteria prior to enrolling and for the duration of the study.
•Subjects with any of the following facial cosmetic treatments within the past 3 months or those who are unwilling to withhold the following facial cosmetic treatments during study including microdermabrasion, intense pulsed light (IPL), peels, laser treatments, acid treatments, or any other medical treatment administered by a physician or skin care professional which is designed to improve skin pigmentation.
•Individuals who have changed any of their hormonal based contraception within 3 months prior to joining the study.
•Current tobacco smoker or a tobacco smoking history of greater than 10 pack-years.

Locations (1)

Integrative Skin and Research

Sacramento, California, United States

Key Dates

Start Date

November 6, 2023

Primary Completion Date

January 11, 2024

Completion Date

January 11, 2024

Last Updated

August 28, 2024

Enrollment

ACTUAL participants

Conditions

HyperpigmentationPost-inflammatory HyperpigmentationAcne

Interventions

Topical Cetyl Tranexamate Mesylate

OTHER

Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars

NCT07058883

Acne Scars

View study

RECRUITINGNA

Reduction of Bacterial Seeding in Total Shoulder Arthroplasty

NCT07406893

Joint ArthroplastyShoulder+2 more

View study

RECRUITINGNA

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 28, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation

Inclusion Criteria

Exclusion Criteria

Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars

Reduction of Bacterial Seeding in Total Shoulder Arthroplasty

The Suitability of Tience® for Treating Acne Scars

Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris

Efficacy of Combined Fractional Er:Glass and Thulium Lasers Versus Microneedling for Atrophic Acne Scars

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors